IGF::OT::IGF: SBIR Phase II, Topic 326: Development of Novel Therapeutic Agents that Target Cancer

Project: Research project

Project Details


Over the past decade, it has become abundantly clear that cancer-initiating stem cell (CSC) elimination is imperative to ?cure? cancer. Unfortunately, most of the existing clinical therapies target the bulk tumor and spare the very small number CSCs comprising
Effective start/end date10/1/169/30/17


  • National Cancer Institute: $1,475,002.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.